Japan Post Bank will launch DCJPY in 2026, linking bank savings with NFTs, tokenized assets, and digital payments.]]>Japan Post Bank will launch DCJPY in 2026, linking bank savings with NFTs, tokenized assets, and digital payments.]]>

Japan Post Bank to Launch DCJPY Digital Currency by 2026

  • Japan Post Bank plans to launch DCJPY in 2026 to modernize savings and attract younger users through digital currency innovation.
  • DCJPY will enable instant conversions between savings accounts and digital use cases like NFTs and tokenized securities.

Japan Post Bank, a giant bank known for its traditional approach, has officially announced plans to issue a digital currency called DCJPY in fiscal 2026.

According to Nikkei Asia, the bank wants to activate more than 190 trillion yen in idle customer funds and entice younger generations back into banking.

Imagine, savings can be instantly converted into digital assets like NFTs and security tokens. There’s no need for a complicated process, and it’s definitely not like the stablecoin model that floats freely on a public blockchain.

Japan Post Bank Sets the Stage for DCJPY on Closed Blockchain Network

DCJPY will operate as a tokenized deposit, meaning it will be fully supervised by the Japanese financial system. Each digital balance in DCJPY will represent a real bank deposit, and the entire infrastructure will run on a closed blockchain network.

So, it’s very different from public stablecoins, which often cause headaches for regulators. Furthermore, DCJPY can be instantly converted from savings balances to digital form and used to transact assets, including security tokens and even NFTs. Yes, it’s that flexible.

DeCurret DCP, a subsidiary of DeCurret Holdings, is the development arm of DeCurret DCP. In fact, since August 2024, this project has been underway quietly.

The following month, they also successfully raised over ¥6.35 billion to strengthen their technological foundation. So, it’s not a trial project. Moreover, Japan Post Bank has over 120 million active accounts. The market is clear, the infrastructure is strong, and the official launch is just a matter of waiting.

Japan Balances Tradition and Innovation in Its Digital Currency Push

On the other hand, the CNF reported that the Japanese Financial Services Authority (FSA) is also processing a license for the country’s first yen stablecoin.

The first player is JPYC Inc., a Tokyo-based fintech company that is ready to launch a stablecoin based on bank deposits and Japanese government bonds. Furthermore, JPYC is also preparing to register as a money transfer service provider to comply with strict regulations.

So, it could be said that Japan is warming up all avenues: traditional banks through DCJPY and startups through JPYC. Which one will go first? It will be interesting to see.

The potential use of DCJPY also extends to social matters. Japan Post Bank plans to enable local governments to use this digital currency to distribute subsidies. If successful, this could be a faster, more transparent, and more cost-effective solution for distributing aid. This is ideal for Japan, where the population is increasingly digital, but still values ​​an orderly system.

Upon closer examination, this move is actually in line with Japan’s own domestic dynamics. Last June, news circulated that several large financial institutions in Japan had quietly begun shifting some of their funds to Bitcoin.

The pressure of mounting national debt and rising bond yields has prompted them to seek refuge. At the same time, the crypto market is beginning to appear more vibrant.

Furthermore, the Bank of Japan’s next decision is expected to trigger a new wave of crypto demand from domestic institutions. Therefore, the launch of DCJPY could serve as a kind of transition bridge between the legacy financial system and the world of digital assets.

]]>
Market Opportunity
Lorenzo Protocol Logo
Lorenzo Protocol Price(BANK)
$0.04989
$0.04989$0.04989
+5.81%
USD
Lorenzo Protocol (BANK) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26